Gastrointestinal satiety signals IV. Apolipoprotein A-IV.
The focus of this article is to review evidence that apolipoprotein A-IV (apo A-IV) acts as a satiety factor. Additionally, information regarding the general involvement of apo A-IV in the regulation of food intake and body weight is stated. Apo A-IV is a glycoprotein synthesized by the human intestine. In rodents, both the small intestine and liver secrete apo A-IV, but the small intestine is the major organ responsible for circulating apo A-IV. There is now solid evidence that the hypothalamus, especially the arcuate nucleus, is another active site of apo A-IV expression. Intestinal apo A-IV synthesis is markedly stimulated by fat absorption and does not appear to be mediated by the uptake or reesterification of fatty acids to form triglycerides. Rather, the local formation of chylomicrons acts as a signal for the induction of intestinal apo A-IV synthesis. Intestinal apo A-IV synthesis is also enhanced by a factor from the ileum, probably peptide tyrosine-tyrosine (PYY). The inhibition of food intake by apo A-IV is mediated centrally. The stimulation of intestinal synthesis and secretion of apo A-IV by lipid absorption are rapid; thus apo A-IV likely plays a role in the short-term regulation of food intake. Other evidence suggests that apo A-IV may also be involved in the long-term regulation of food intake and body weight, as it is regulated by both leptin and insulin. Chronic ingestion of a high-fat diet blunts the intestinal as well as the hypothalamic apo A-IV response to lipid feeding. It also suppresses apo A-IV gene expression in the hypothalamus. Whereas it is tempting to speculate that apo A-IV may play a role in diet-induced obesity, we believe the confirmation of such a proposal awaits further experimental evidence.
Tso
Patrick
P
Department of Pathology, University of Cincinnati Medical Center, OH 45267, USA. tsopp@email.uc.edu
Sun
William
W
Liu
Min
M
D000818:Animals; D001054:Apolipoproteins A / Q000008:administration & dosage / Q000502:physiology*; D001835:Body Weight / Q000502:physiology; D004435:Eating / Q000187:drug effects; D041981:Gastrointestinal Tract / Q000502:physiology*; D006801:Humans; D007262:Infusions, Intravenous; D007276:Injections, Intraventricular; D019894:Peptide YY / Q000502:physiology; D012528:Satiety Response / Q000502:physiology*
D001054:Apolipoproteins A; C022205:apolipoprotein A-IV; D019894:Peptide YY